The perception of anaphylaxis as a rare medical emergency is becoming obsolete as global prevalence data reveals lifetime occurrence rates reaching 5.1% of the population. This dramatic shift reflects not only better recognition but also the genuine surge in allergic diseases affecting both children and adults worldwide. The World Allergy Organization's comprehensive review reveals how this potentially fatal systemic reaction has evolved from medical rarity to public health concern.
The pathophysiology centers on mast cell degranulation through IgE-mediated pathways, releasing tryptase and histamine that trigger rapid cardiovascular and respiratory compromise. Trigger patterns show distinct age demographics: dairy, peanuts, and tree nuts dominate pediatric cases, while beta-lactam antibiotics and NSAIDs primarily affect adults. Geographic variations in insect venom sensitivity add complexity to prevention strategies. Diagnosis remains clinical, requiring recognition of rapid multisystem involvement even when classic skin symptoms are absent.
Intranasal epinephrine represents a significant treatment advancement, offering needle-free administration that could improve patient compliance and reduce treatment barriers. This innovation addresses practical challenges of traditional intramuscular injection, particularly in pediatric populations or patients with needle phobia. However, the review emphasizes that antihistamines and corticosteroids, while symptomatically helpful, cannot reverse the life-threatening cardiovascular collapse. The rising prevalence suggests environmental or lifestyle factors are amplifying allergic sensitization, making rapid recognition and appropriate treatment protocols increasingly critical for healthcare providers and the general public.